Form 8-K - Current report:
SEC Accession No. 0001193125-23-203836
Filing Date
2023-08-04
Accepted
2023-08-04 16:02:22
Documents
12
Period of Report
2023-08-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d471821d8k.htm   iXBRL 8-K 27027
  Complete submission text file 0001193125-23-203836.txt   152993

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230803.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230803_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230803_pre.xml EX-101.PRE 11703
6 EXTRACTED XBRL INSTANCE DOCUMENT d471821d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 231143931
SIC: 2836 Biological Products, (No Diagnostic Substances)